Neil Kumar Sells 40,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total transaction of $2,877,600.00. Following the sale, the chief executive officer owned 695,686 shares in the company, valued at $50,047,650.84. This represents a 5.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neil Kumar also recently made the following trade(s):

• On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $73.97, for a total transaction of $2,958,800.00.
• On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.64, for a total value of $2,240,021.04.
• On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.40, for a total value of $2,976,000.00.
• On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The shares were sold at an average price of $65.84, for a total value of $1,722,111.04.

BridgeBio Pharma Trading Down 1.1%

Shares of BridgeBio Pharma stock opened at $75.25 on Friday. BridgeBio Pharma, Inc. has a 1 year low of $28.33 and a 1 year high of $84.94. The company has a market cap of $14.50 billion, a P/E ratio of -18.00 and a beta of 1.13. The stock has a 50-day moving average price of $75.60 and a 200 day moving average price of $63.08.

Institutional Investors Weigh In On BridgeBio Pharma

A number of large investors have recently added to or reduced their stakes in BBIO. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth about $25,000. Aster Capital Management DIFC Ltd bought a new position in BridgeBio Pharma in the 3rd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd bought a new position in BridgeBio Pharma in the 3rd quarter worth approximately $34,000. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma during the first quarter worth approximately $35,000. Finally, First Horizon Corp bought a new stake in shares of BridgeBio Pharma in the third quarter valued at approximately $36,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BBIO. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday. Piper Sandler increased their price objective on BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Truist Financial upped their target price on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average price target of $81.55.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.